Integris Medtech Ltd. IPO

Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.

Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments.

The company’s business is structured into two core divisions:

  • Cardiovascular Devices – encompassing drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions.
  • Laboratory Solutions – covering clinical, research, and industrial laboratory equipment, reagents, and consumables, along with services such as instrument installation, maintenance, and calibration through its BioCal™ brand.

Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors.

Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America.

As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.

Company Financials (Restated Consolidated)

Period Ended30 Jun 202531 Mar 202531 Mar 202431 Mar 2023
Assets4,019.623,641.342,989.202,553.87
Total Income508.931,959.581,582.261,369.66
Profit After Tax267.5770.68-4.88-40.54
EBITDA78.73309.40190.45168.82
NET Worth3,889.992,752.522,681.022,629.52
Reserves and Surplus2,299.841,150.741,135.711,073.12
Total Borrowing793.421,729.46813.10556.54
Amount in ₹ Crore

Recently Listed IPOs in Medical Equipment & Supplies

CompanyIssue TypeIssue SizeIssue PricePE RatioListing Day CloseListing Gain/Loss %LTP
Sahajanand Medical Technologies Ltd.Mainboard₹475.48 Cr₹34450.59₹377.65+9.78%₹527.60
Molbio Diagnostics Ltd.Mainboard₹939.70 Cr₹80755.43₹1,041.70+29.08%₹1,495.50
Q-Line Biotech Ltd.SME₹214.48 Cr₹34320.82₹474.60+38.37%₹396.80
 

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

#Issue ObjectsEst Amt (₹ Cr.)
1Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:509.85
2The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd.93.87
3The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd.415.98
4General Corporate Purposes 
 Total1,019.70

Key Performance Indicator (KPI)

KPIMar 31, 2025
ROE5.35%
ROCE14.51%
RoNW1.48%
PAT Margin3.72%
EBITDA Margin16.26%
NAV316.09

IPO Valuation

Valuation MetricPre IPOPost IPO
EPS (₹)6.52 

Integris Medtech IPO Details

IPO Date 27 Nov to 1 Dec, 2026
Listing Date Fri, Dec 4, 2026T
Face Value ₹1 per share
Price Band
Sale Type Fresh capital cum OFS
Issue Type Bookbuilding IPO
Listing At BSE, NSE
Fresh Issue [.] shares (agg. up to ₹600.00 Cr)
Offer for Sale 1,08,37,266 shares of ₹1 (agg. up to ₹[.] Cr)
Share Holding Pre Issue 10,83,38,049 shares

Integris Medtech IPO Promoter Holding

The promoters of the company are Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh and Punita Sharma.

Share Holding Pre Issue83.24%
Share Holding Post Issue 

SHARIAH SCREENING for - Integris Medtech Ltd. IPO

BUSINESS SCREEN

FINANCIAL RATIOS

As per our analysis and Based on the information we have, this is the output.
Allah knows best.
If you find this result mistaken or questionable, let us know via email at info (@) halalstock.in

Spread the Knowledge - Share the Latest IPO Updates and Shariah Compliant IPO's.

Latest Current & Upcoming IPOs in BSE & NSE - Including Shariah Compliant.

The IPO dashboard offers insights on the Latest Current & Upcoming IPOs in BSE & NSE. It also evaluates IPOs for Shariah compliance, ensuring alignment with Islamic principles for ethical investment choices.

IPO

Integris Medtech IPO Details

Last Updated on November 21, 2026 Integris Medtech Ltd. IPO Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises,

Read More »

Dear Halal Stock Users,

If you believe our website is a valuable resource,
we invite you to support us.
Your contribution ensures free access for all
and fuels future development.

You can contribute as little as
100, 200, 500 & so…
every bit counts.

Thank you for your support!